Lixte Biotechnology Holdings, Inc.
(NASDAQ : LIXT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.29%219.010.0%$2036.26m
BIIBBiogen, Inc. -6.10%349.201.7%$1210.14m
SNSSSunesis Pharmaceuticals, Inc. 5.84%11.780.7%$823.47m
NVAXNovavax, Inc. -0.38%191.5179.8%$817.25m
AMGNAmgen, Inc. 0.83%240.701.3%$642.72m
BNTXBioNTech SE -0.39%228.600.0%$570.70m
VRTXVertex Pharmaceuticals, Inc. 2.44%192.091.9%$540.48m
GILDGilead Sciences, Inc. 1.23%67.471.0%$481.67m
REGNRegeneron Pharmaceuticals, Inc. 1.53%537.922.7%$392.04m
OCGNOcugen, Inc. 0.99%7.640.0%$349.43m
ILMNIllumina, Inc. 0.16%469.903.5%$347.50m
ALXNAlexion Pharmaceuticals, Inc. 0.54%180.802.0%$333.51m
TXG10X Genomics, Inc. -1.92%197.550.0%$175.30m
EXASEXACT Sciences Corp. -0.47%130.3618.1%$175.23m
BNGOBionano Genomics, Inc. -0.97%7.180.0%$154.61m

Company Profile

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company, that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The firm focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.